LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | XMD16-144 | 1.11 | uM | LJP5 | 2 | M09 | 72 | hr | 1097 | 1392 | 3877 | 0.3590 | 0.1396 |
BT-20 | XMD16-144 | 1.11 | uM | LJP5 | 3 | M09 | 72 | hr | 1097 | 1347 | 3925 | 0.3432 | 0.1180 |
BT-20 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 1097 | 1344 | 3735 | 0.3598 | 0.1216 |
BT-20 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 1097 | 1315 | 3877 | 0.3391 | 0.1045 |
BT-20 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 1097 | 1277 | 3925 | 0.3253 | 0.0860 |
BT-20 | XMD16-144 | 10 | uM | LJP5 | 1 | M07 | 72 | hr | 1097 | 1015 | 3735 | 0.2717 | -0.0431 |
BT-20 | XMD16-144 | 10 | uM | LJP5 | 2 | M07 | 72 | hr | 1097 | 1168 | 3877 | 0.3012 | 0.0349 |
BT-20 | XMD16-144 | 10 | uM | LJP5 | 3 | M07 | 72 | hr | 1097 | 971 | 3925 | 0.2474 | -0.0643 |
BT-20 | Erlotinib | 0.04 | uM | LJP5 | 1 | M24 | 72 | hr | 1097 | 3122 | 3735 | 0.8358 | 0.8070 |
BT-20 | Erlotinib | 0.04 | uM | LJP5 | 2 | M24 | 72 | hr | 1097 | 3202 | 3877 | 0.8257 | 0.8004 |
BT-20 | Erlotinib | 0.04 | uM | LJP5 | 3 | M24 | 72 | hr | 1097 | 3808 | 3925 | 0.9701 | 0.9672 |
BT-20 | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 1097 | 3137 | 3735 | 0.8398 | 0.8119 |
BT-20 | Erlotinib | 0.12 | uM | LJP5 | 2 | M23 | 72 | hr | 1097 | 3267 | 3877 | 0.8425 | 0.8204 |
BT-20 | Erlotinib | 0.12 | uM | LJP5 | 3 | M23 | 72 | hr | 1097 | 3439 | 3925 | 0.8761 | 0.8612 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 1097 | 3178 | 3735 | 0.8508 | 0.8253 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 2 | M22 | 72 | hr | 1097 | 3320 | 3877 | 0.8562 | 0.8365 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 3 | M22 | 72 | hr | 1097 | 3490 | 3925 | 0.8891 | 0.8761 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 1097 | 3381 | 3735 | 0.9052 | 0.8904 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 1097 | 3027 | 3877 | 0.7806 | 0.7457 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 1097 | 3089 | 3925 | 0.7869 | 0.7557 |
BT-20 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 1097 | 3165 | 3735 | 0.8473 | 0.8211 |
BT-20 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 1097 | 3451 | 3877 | 0.8899 | 0.8760 |
BT-20 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 1097 | 3079 | 3925 | 0.7844 | 0.7526 |
BT-20 | Erlotinib | 10 | uM | LJP5 | 1 | M19 | 72 | hr | 1097 | 2638 | 3735 | 0.7063 | 0.6427 |
BT-20 | Erlotinib | 10 | uM | LJP5 | 2 | M19 | 72 | hr | 1097 | 2710 | 3877 | 0.6989 | 0.6428 |